Regeneron says its COVID-19 antibody drug could be ready by fall

Regeneron Pharmaceuticals said its experimental antibody drug for COVID-19 could be ready for patients by fall, Bloomberg reported. 

The drug is a mixture of two antibodies, manufactured versions of proteins that are typically produced as part of an immune response to a virus, according to Bloomberg.

Regeneron plans to study the drug in humans for the first time in June. 

Other drugmakers are also developing antibody drugs for COVID-19, including Eli Lilly, AstraZeneca and Vir Biotechnology. 

Read the full article here.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars